AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer
Publication date: June 2026 Source: Clinical Colorectal Cancer, Volume 25, Issue 2 Author(s): Gertjan Rasschaert, Allyson M. Peddle, Sara Verbandt, Sabine Tejpar, Nicholas P. West, Jenny Ross, Julie Switzky, Morad Marco Balas, Ken Edwards, Gabor Kari, Sue Griffin, Daniel N. Cohen, Emily Hammatt, Edmund K. Moon
AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000216?dgcid=rss_sd_all
AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000216?dgcid=rss_sd_all
“AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer.” Clinical Colorectal Cancer.
@article{article40730,
title = {AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000216?dgcid=rss_sd_all}
}